Shire has laid out an ambitious goal of effectively doubling its revenue in the next few years, bringing in $10 billion by 2020, and CEO Flemming Ornskov said the acquisitive biotech has a bullpen of potential therapies that will help it come through on that promise.

…read more

Source: Shire hails its best-ever pipeline with a ‘busy’ R&D year ahead


0 No comments